Bifunctional Degraders for Selective p300 Protein Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective bifunctional protein degraders that can effectively target and degrade CBP/p300 proteins, which are implicated in various cancers, while minimizing toxicity to non-cancerous cells.
Innovation Solution
The development of compounds of Formula I (T-L-C), and their pharmaceutically acceptable salts, solvates, or stereoisomers, which are designed to selectively degrade p300 proteins by forming a ternary complex with an E3 ligase complex, leading to proteasomal degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bifunctional protein degraders are used to target CBP/p300 proteins, then cancer treatment efficacy is improved, but toxicity to non-cancerous cells increases
Solution Approach 1:
The patent applies local quality by designing the bifunctional degrader molecule with distinct functional regions: one end specifically targets p300 protein while the other end recruits the E3 ligase complex. This localized functional differentiation enables selective degradation of p300 in cancer cells without affecting non-cancerous cells, resolving the contradiction between treatment efficacy and toxicity by making the drug action highly specific to the target protein in the disease context.
Solution Approach 2:
The patent utilizes parameter changes by optimizing the chemical structure, binding affinity, and molecular properties of the bifunctional degrader to achieve selective p300 degradation. By adjusting parameters such as the linker length, functional group composition, and binding constant, the drug can effectively degrade p300 in cancer cells while maintaining safety margins for normal cells, thus resolving the toxicity versus efficacy contradiction.
2Reliability
If selective p300 degraders are designed to achieve strong selectivity, then transcriptional output inhibition in cancer cells is improved, but molecular complexity of the compound increases
Solution Approach 1:
The patent applies segmentation by dividing the bifunctional degrader into two distinct functional modules connected by a linker: a p300-binding moiety and an E3 ligase-recruiting moiety. This segmented architecture allows each module to be optimized independently for its specific binding function, achieving high selectivity for p300 while managing molecular complexity through modular design rather than a single complex undifferentiated structure.
Solution Approach 2:
The patent uses an intermediary approach by introducing a linker molecule that mediates between the p300-binding domain and the E3 ligase-recruiting domain. This intermediary linker allows the two functional elements to be spatially separated and independently optimized, enabling strong selectivity for p300 while keeping the overall molecular complexity manageable through the use of a relatively simple connecting structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate strong selectivity for p300 over CBP, resulting in a time-dependent loss of p300 activity, reduced enhancer acetylation, and transcriptional output in cancer cells, with limited toxicity to untransformed cells.
Implementation Method 1
Bifunctional protein degraders are heterobifunctional compounds that simultaneously bind a target protein and an E3 ligase complex, resulting in the transfer of ubiquitin and initiating a process ultimately causing the proteasomal degradation of the target protein
Data Source
AI summary
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., for degrading certain proteins such as p300/CBP proteins).